Amneal Pharmaceuticals
(NASDAQ) AMRX
Amneal Pharmaceuticals Financials at a Glance
Market Cap
$5.17B
Revenue (TTM)
$3.05B
Net Income (TTM)
$122.36M
EPS (TTM)
$0.37
P/E Ratio
43.43
Dividend
$0.00
Beta (Volatility)
1.08 (Average)
Dividend
$0.00
Beta (Volatility)
1.08 (Average)
Price
$16.25
Volume
2,370,233.2
Open
$16.11
Price
$16.25
Volume
2,370,233.2
Open
$16.11
Previous Close
$16.24
Daily Range
$15.73 - $16.36
52-Week Range
$7.67 - $16.61
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
1.08 (Average)
Price
$16.25
Volume
2,370,233.2
Open
$16.11
Previous Close
$16.24
Daily Range
$15.73 - $16.36
52-Week Range
$7.67 - $16.61
Estimated Earnings Date
Aug 4, 2026
AMRX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Amneal Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
8,500
CEO
Chintu Patel, PhD; Chirag K. Patel, PhD
Website
www.amneal.comHeadquarters
Bridgewater, NJ 08807, US
AMRX Financials
Key Financial Metrics (TTM)
Gross Margin
39%
Operating Margin
12%
Net Income Margin
4%
Return on Equity
0%
Return on Capital
13%
Return on Assets
3%
Earnings Yield
2.30%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$5.17B
Shares Outstanding
319.02M
Volume
2.37M
Avg. Volume
1.78M
Financials (TTM)
Gross Profit
$1.14B
Operating Income
$423.09M
EBITDA
$603.87M
Operating Cash Flow
$339.99M
Capital Expenditure
-$70.06M
Free Cash Flow
$269.93M
Cash & ST Invst.
$310.87M
Total Debt
$2.74B
Amneal Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$722.52M
+3.9%
Gross Profit
$320.11M
+25.1%
Gross Margin
44.31%
N/A
Market Cap
$5.17B
N/A
Market Cap/Employee
$622.67K
N/A
Employees
8,300
N/A
Net Income
$62.50M
+412.5%
EBITDA
$176.73M
+14.3%
Quarterly Fundamentals
Total Cash
$197.66M
+234.0%
Total Debt
$2.70B
+4.5%
Accounts Receivable
$902.65M
+12.8%
Inventory
$641.62M
+6.7%
Long Term Debt
$2.68B
+19.3%
Short Term Debt
$21.49M
-93.6%
Return on Assets
3.46%
N/A
Return on Invested Capital
12.78%
N/A
Free Cash Flow
-$42.59M
-290.2%
Operating Cash Flow
-$28.73M
-487.8%